Kalyan Bhamidimarri, MD
Gastroenterology · Weston, FLNPI 1154439156
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Madrigal Pharmaceuticals at 44.8% of the total. Among gastroenterology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $529.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Madrigal Pharmaceuticals$43K
- AbbVie$11K
- Ipsen Biopharmaceuticals, Inc$7K
- Gilead$7K
- Mirum Pharmaceuticals, Inc.$7K
- Intercept Pharmaceuticals, Inc.$5K
- plus $16K from 16 others
Across 63 payments — averaging $1330.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$62K
- Mallinckrodt Enterprises LLC$21K
- Merck$500
What the payments were for
- Consulting fees$29,38030%
- Speaking & faculty fees$54,17656%
- Travel & lodging$5,6696%
- Food & beverage$7,1107%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Madrigal Pharmaceuticals | 58 | $43,114 |
| AbbVie(2 entities) | 35 | $11,055 |
| Ipsen Biopharmaceuticals, Inc | 8 | $7,374 |
| Gilead | 19 | $7,374 |
| Mirum Pharmaceuticals, Inc. | 17 | $7,019 |
| Intercept Pharmaceuticals, Inc. | 10 | $4,668 |
| Dova Pharmaceuticals | 4 | $4,312 |
| Orphalan Inc | 3 | $3,247 |
| Albireo Pharma, Inc. | 1 | $2,925 |
| Theratechnologies Inc. | 1 | $2,000 |
| AstraZeneca | 5 | $1,859 |
| Johnson & Johnson(2 entities) | 4 | $566 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $189 |
| Boston Scientific | 3 | $177 |
| Novo Nordisk | 2 | $145 |
| Perspectum Diagnostics Ltd | 1 | $107 |
| Mallinckrodt Enterprises LLC | 1 | $73 |
| Aimmune Therapeutics, Inc. | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Exelixis Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$41,885
- Mavyret$10,053
- Livmarli$6,496
- DOPTELET$4,231
- IQIRVO$4,007
- CUVRIOR$3,172
- Bylvay$2,925
- Vemlidy$2,060
- Kanuma$810
- RESMETIROM$270
- OCALIVA$254
- Strensiq$125
- RYBELSUS$125
- HABIB ENDOHPB$113
- LiverMultiScan$107
How this compares
$96,335 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 23 | $216,715 |
| VemlidyTenofovir Alafenamide | 50 | $72,387 |
| XifaxanRifaximin | 20 | $60,171 |
| RezdiffraResmetirom | 12 | $56,274 |
| Ursodiol | 52 | $8,364 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 29 | $322 |
| Nadolol | 11 | $289 |
| Carvedilol | 30 | $287 |
| Omeprazole | 20 | $109 |
| Spironolactone | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $4,668 | $216,71523 claims |
| GileadVemlidy | $7,374 | $72,38750 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $189 | $60,17120 claims |
| Madrigal PharmaceuticalsRezdiffra | $43,114 | $56,27412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Weston
- Mohammad AlomariWeston$132K
- Fnu Asad-Ur-RahmanWeston$84K
- Samuel GidayOrlando$2M
- Lukasz KwapiszMiami$1.2M
- Jennifer Seminerio-DiehlOrlando$1.1M
- Udayakumar NavaneethanSaint Petersburg$1.1M
- Ronen AraiCoral Springs$1.1M
- Charles SninskyGainesville$983K
- Peter DraganovGainesville$832K
- Arin NewmanMiami Beach$716K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.